Prediction of benralizumab response in severe asthma using clinical parameters and early treatment response:a national, real life study
Recruiting
- Conditions
- Asthma
- Registration Number
- NL-OMON27637
- Lead Sponsor
- Medical Centre Leeuwarden
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 200
Inclusion Criteria
In order to be eligible to participate in this study, a subject must meet all of the following criteria:
Included in RAPSODI, receiving benralizumab treatment
RAPSODI inclusion criteria:
- Severe asthma patient in the Netherlands
- =18 years old
Exclusion Criteria
N/A
Study & Design
- Study Type
- Observational non invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Benralizumab response is the main endpoint. Benralizumab response will be defined as continuing benralizumab at the 1 year point. A multivariable model based on (changes in) 3 month patient reported outcome measures and baseline characteristics will be constructed, predicting benralizumab response in severe asthma patients.
- Secondary Outcome Measures
Name Time Method Change in the model’s performance (f.e. AUROC, predictive values) by adding the 3 month patient reported outcome measures will be assessed and reported.